Cargando…

2412. Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side-effects: Two Hospitals Experience

BACKGROUND: Clostridioides difficile is the most common hospital-acquired pathogen with an unchanged infection prevalence between 2011–2015. The data regarding the effectiveness of chemical prophylaxis to prevent recurrent C. difficile infection (CDI) are conflicting. METHODS: We conducted a retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zacharioudakis, Ioannis, Zervou, Fainareti, Dubrovskaya, Yanina, Phillips, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810335/ http://dx.doi.org/10.1093/ofid/ofz360.2090

Ejemplares similares

2351. Rate and Consequences of Missed Clostridioides (Clostridium) difficile Infection Diagnosis from Non-disclosure of Clostridioides difficile Multiplex PCR Results. Two-Hospital Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

Association of Community Factors with Hospital-onset Clostridioides (Clostridium) difficile Infection: A Population Based U.S.-wide Study
por: Zacharioudakis, Ioannis M., et al.
Publicado: (2019)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

Graft-Versus-Host Disease Prophylaxis after Transplantation: A Network Meta-Analysis
por: Ziakas, Panayiotis D., et al.
Publicado: (2014)

Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data
por: Grigoras, Christos A., et al.
Publicado: (2016)

Prevalence of Clostridium difficile Infection among Solid Organ Transplant Recipients: A Meta-Analysis of Published Studies
por: Paudel, Suresh, et al.
Publicado: (2015)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Prevalence and Clinical Outcomes of Clostridium difficile Infection in the Intensive Care Unit: A Systematic Review and Meta-Analysis
por: Karanika, Styliani, et al.
Publicado: (2015)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

Asymptomatic Carriers of Toxigenic C. difficile in Long-Term Care Facilities: A Meta-Analysis of Prevalence and Risk Factors
por: Ziakas, Panayiotis D., et al.
Publicado: (2015)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

696. Effectiveness of Oral Vancomycin as Prophylaxis against Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant Patients
por: Reitmeyer, Kelly M, et al.
Publicado: (2023)

T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications
por: Zacharioudakis, Ioannis M., et al.
Publicado: (2018)

Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011: A nationwide study
por: Ziakas, Panayiotis D., et al.
Publicado: (2016)

2413. Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections.
por: Vyas, Nikunj M, et al.
Publicado: (2019)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection – A Systematic Review
por: Knudsen, Maja Johanne Søndergaard, et al.
Publicado: (2023)

Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department
por: Zacharioudakis, Ioannis M., et al.
Publicado: (2019)

658. Cost-effectiveness of Molecular Diagnostic Assays for the Therapy of Severe Sepsis and Septic Shock in the Emergency Department
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Analysis of the impact of secondary prophylaxis on Clostridioides difficile recurrence in critically ill adults
por: Connor, Kathryn A, et al.
Publicado: (2020)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry
por: Andreatos, Nikolaos, et al.
Publicado: (2017)

105. Evaluation of a Multiplex PCR Panel for the Microbiologic Diagnosis of Pneumonia in Hospitalized Patients: A Retrospective Analysis from an Academic Medical Center
por: Zacharioudakis, Ioannis, et al.
Publicado: (2020)

Evaluation of BioFire® FilmArray® Pneumonia Panel in Bronchoalveolar Lavage Samples From Immunocompromised Patients With Suspected Pneumonia
por: Li-Geng, Tony, et al.
Publicado: (2023)

391. Evaluation of oral vancomycin treatment for hospital-acquired Clostridioides difficile infection prophylaxis in a community hospital: A retrospective cohort study
por: Meng, Qingqing, et al.
Publicado: (2022)

222. Oral Step-Down Therapy for Uncomplicated Enterococcus Bacteremia
por: Ni, Jessica, et al.
Publicado: (2023)

213. Prophylactic oral vancomycin for Clostridioides difficile in allogeneic hematopoietic stem cell transplant recipients
por: Ogawa, Lauren, et al.
Publicado: (2022)

Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study
por: Umemura, Takumi, et al.
Publicado: (2019)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
por: Moran, Gisele, et al.
Publicado: (2018)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0oqeiimnlhc465ekhmo9q0jlk8